The Short Version
The claim accurately describes the treatment arms and primary duration of SURMOUNT-1. The primary NEJM report, study protocol and trial registry confirm that this phase 3 trial assigned participants to once-weekly subcutaneous tirzepatide at target doses of 5 mg, 10 mg or 15 mg, or placebo, over 72 weeks.